| Literature DB >> 34612847 |
Kusum Menon1, Luregn J Schlapbach2, Samuel Akech3, Andrew Argent4, Paolo Biban5, Enitan D Carrol6, Kathleen Chiotos7, Mohammod Jobayer Chisti8, Idris V R Evans9, David P Inwald10, Paul Ishimine11, Niranjan Kissoon12, Rakesh Lodha13, Simon Nadel14, Cláudio Flauzino Oliveira15, Mark Peters16, Benham Sadeghirad17, Halden F Scott18, Daniela C de Souza19, Pierre Tissieres20, R Scott Watson21, Matthew O Wiens22,23, James L Wynn24, Jerry J Zimmerman21, Lauren R Sorce25.
Abstract
OBJECTIVE: To determine the associations of demographic, clinical, laboratory, organ dysfunction, and illness severity variable values with: 1) sepsis, severe sepsis, or septic shock in children with infection and 2) multiple organ dysfunction or death in children with sepsis, severe sepsis, or septic shock. DATA SOURCES: MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials were searched from January 1, 2004, and November 16, 2020. STUDY SELECTION: Case-control studies, cohort studies, and randomized controlled trials in children greater than or equal to 37-week-old postconception to 18 years with suspected or confirmed infection, which included the terms "sepsis," "septicemia," or "septic shock" in the title or abstract. DATA EXTRACTION: Study characteristics, patient demographics, clinical signs or interventions, laboratory values, organ dysfunction measures, and illness severity scores were extracted from eligible articles. Random-effects meta-analysis was performed. DATA SYNTHESIS: One hundred and six studies met eligibility criteria of which 81 were included in the meta-analysis. Sixteen studies (9,629 patients) provided data for the sepsis, severe sepsis, or septic shock outcome and 71 studies (154,674 patients) for the mortality outcome. In children with infection, decreased level of consciousness and higher Pediatric Risk of Mortality scores were associated with sepsis/severe sepsis. In children with sepsis/severe sepsis/septic shock, chronic conditions, oncologic diagnosis, use of vasoactive/inotropic agents, mechanical ventilation, serum lactate, platelet count, fibrinogen, procalcitonin, multi-organ dysfunction syndrome, Pediatric Logistic Organ Dysfunction score, Pediatric Index of Mortality-3, and Pediatric Risk of Mortality score each demonstrated significant and consistent associations with mortality. Pooled mortality rates varied among high-, upper middle-, and lower middle-income countries for patients with sepsis, severe sepsis, and septic shock (p < 0.0001).Entities:
Mesh:
Year: 2022 PMID: 34612847 PMCID: PMC8670345 DOI: 10.1097/CCM.0000000000005294
Source DB: PubMed Journal: Crit Care Med ISSN: 0090-3493 Impact factor: 9.296
Characteristics of All Included Studies
| Characteristic | Studies in Meta-Analysis ( | Patients From Meta-Analysis ( | Narrative Studies ( | Patients From Narrative Studies ( |
|---|---|---|---|---|
| Publication year | ||||
| 2004–2008 | 8 (9.9) | 7,861 (5.1) | 6 (24.0) | 374 (6.4) |
| 2009–2012 | 5 (6.2) | 1,499 (0.1) | 0 (0) | 0 (0) |
| 2013–2016 | 13 (16.0) | 53,340 (34.4) | 7 (28.0) | 1,046 (18.0) |
| 2017–2020 | 55 (67.9) | 91,974 (59.4) | 12 (48.0) | 4,392 (75.6) |
| Participating sites | ||||
| 1 | 58 (71.6) | 17,937 (11.6) | 22 (88.0) | 4,185 (72.0) |
| 2–5 | 3 (3.7) | 1,281 (0.8) | 0 (0) | 0 (0) |
| 6–10 | 6 (7.4) | 2,035 (1.3) | 0 (0) | 0 (0) |
| > 10 | 14 (17.3) | 133,421 (86.3) | 3 (12.0) | 1,627 (28.8) |
| Region of primary site | ||||
| North America | 15 (18.5) | 136,120 (88.0) | 8 (32.0) | 2,312 (39.8) |
| Latin America and Caribbean | 13 (16.0) | 3,387 (2.2) | 2 (8.0) | 57 (1.0) |
| Europe and Central Asia | 13 (16.0) | 3,807 (2.5) | 7 (28.0) | 694 (11.9) |
| East Asia and Pacific | 19 (23.5) | 8,053 (5.2) | 1 (4.0) | 1,510 (26.0) |
| South Asia | 14 (17.3) | 1,585 (1.0) | 3 (12.0) | 249 (4.3) |
| Middle East and North Africa | 5 (6.2) | 541 (0.3) | 3 (12.0) | 585 (10.1) |
| Sub-Saharan Africa | 2 (2.5) | 1,181 (0.8) | 1 (4.0) | 405 (7.0) |
| World Bank Income classification | ||||
| High income country | 33 (40.7) | 142,364 (92.0) | 14 (56.0) | 4,351 (7.5) |
| Upper middle-income country | 30 (37.0) | 9,377 (6.1) | 5 (20.0) | 528 (9.1) |
| Lower middle-income country | 17 (21.0) | 1,812 (1.2) | 6 (24.0) | 923 (15.9) |
| Lower income country | 1 (1.2) | 1,121 (0.7) | 0 (0) | 0 (0) |
| Study design | ||||
| Randomized controlled trial | 1 (1.2) | 50 (0.03) | 0 (0) | 0 (0) |
| Prospective cohort | 38 (46.9) | 9,634 (6.2) | 14 (56.0) | 1,160 (20.0) |
| Retrospective cohort | 37 (45.7) | 145,291 (94.1) | 10 (40.0) | 4,130 (71.1) |
| Case-control | 5 (6.2) | 499 (0.3) | 1 (4.0) | 72 (1.2) |
| Primary study setting | ||||
| PICU | 68 (84.0) | 136,599 (88.3) | 21 (84.0) | 5,072 (87.3) |
| Emergency department | 8 (9.9) | 2,078 (1.3) | 4 (16.0) | 932 (16.0) |
| Ward | 7 (8.6) | 12,423 (8.0) | 0 (0) | 0 (0) |
| Other | 3 (3.7) | 3,574 (2.3) | 0 (0) | 0 (0) |
aSite of the corresponding author and or location of research ethics approval using the World Bank Classification of 2019–2020.
bSecondary analysis of a randomized controlled trial.
cTwo settings were unspecified and one included all hospital locations. In addition, some studies included more than one specified study location resulting in a total of more than 81 study locations.
Patient Characteristics for All Included Studies
| Characteristic | Studies in Meta-Analysis ( | Patients in Meta-Analysis ( | Narrative Studies ( | Patients in Narrative Studies ( |
|---|---|---|---|---|
| Age groups included | ||||
| Neonates (0–30 d) | 41 (50.6) | 127,574 (82.5) | 11 (44.0) | 3,657 (62.9) |
| Babies (31–90 d) | 70 (86.4) | 151,730 (98.1) | 22 (88.0) | 1,510 (26.0) |
| Infants (91 d to 1 yr) | 80 (98.8) | 154,452 (99.9) | 24 (96.0) | 5,719 (98.4) |
| Toddlers (2–5 yr) | 79 (97.5) | 154,380 (99.8) | 24 (96.0) | 5,812 (100) |
| School age (6–12 yr) | 73 (90.1) | 152,810 (98.8) | 22 (88.0) | 5,652 (97.2) |
| Adolescents (13–16 yr) | 62 (76.5) | 151,283 (97.8) | 19 (76.0) | 5,248 (90.3) |
| Young adults (17–18 yr) | 44 (54.3) | 144,616 (93.5) | 13 (52.0) | 3,757 (64.6) |
| Population studied | ||||
| Bronchiolitis | 1 (1.2) | 72 (0.0) | 0 (0) | |
| Meningococcal infections | 2 (2.5) | 1,151 (0.7) | 1 (4.0) | 151 (2.6) |
| Pneumonia | 1 (1.2) | 222 (0.1) | 1 (4.0) | 160 (2.8) |
| Diarrheal illness | 2 (2.5) | 270 (0.2) | 0 (0) | 0 (0) |
| Severe acute malnutrition | 1 (1.2) | 50 (0.0) | 0 (0) | 0 (0) |
| Bone marrow transplant | 0 (0) | 0 (0) | 1 (4.0) | 567 (9.8) |
| Oncology—general | 4 (4.9) | 768 (0.5) | 1 (4.0) | 99 (1.7) |
| Oncology—febrile neutropenia | 1 (1.2) | 151 (0.1) | 0 (0) | 0 (0) |
| Emergency department patients | 5 (6.2) | 1,664 (1.1) | 4 (16.0) | 740 (12.7) |
| Hospital ward patients | 6 (7.4) | 24,778 (16.0) | 0 (0) | 0 (0) |
| Any PICU admission | 58 (71.6) | 125,539 (81.2) | 17 (68.0) | 4,095 (70.5) |
| Sepsis definition used | ||||
| 2001 SCCM/ACCP criteria | 7 (8.6) | 2,317 (1.5) | 2 (8.0) | 93 (1.6) |
| 2005 International Pediatric Sepsis Consensus Conference | 57 (70.4) | 56,377 (36.4) | 17 (68.0) | 5,274 (90.7) |
| ACCM 2002 | 2 (2.5) | 126 (0.1) | 1 (4.0) | 57 (0.1) |
| ACCM 2007 | 1 (1.2) | 1,299 (0.8) | 1 (4.0) | 71 (1.2) |
| | 6 (7.4) | 86,594 (56.0) | 0 (0) | 0 (0) |
| Bone criteria | 2 (2.5) | 431 (0.3) | 2 (8.0) | 166 (2.9) |
| Sepsis-3 | 2 (2.5) | 7,091 (4.6) | 0 (0) | 0 (0) |
| Other | 4 (4.9) | 439 (0.3) | 2 (8.0) | 151 (2.6) |
ACCM = American College of Critical Care Medicine, ACCP = American College of Chest Physicians, SCCM = Society of Critical Care Medicine.
aValues for age groups from eligible articles were included in category that provided the closest approximation to the classification used in the article. Articles could have patients from more than one age group resulting in totals being > 100%.
b1. Bone RC, et al: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101:1644–1655. 2. Levy et al (22). 3. Carcillo JA, et al: Clinical practice parameters for hemodynamic support of pediatric and neonatal patients in septic shock. Crit Care Med 2002; 30:1365–1378. 4. Goldstein et al (3). 5. Brierley J, et al: Clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock: 2007 update from the American College of Critical Care Medicine. Crit Care Med 2009; 37:666–688. 6. Singer M, et al: The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016; 315:801–810.
cThree papers referred to hospital guidelines and one defined sepsis as tachycardia plus hypothermia (35.0°C) or hyperthermia (38.5°C), or abnormal WBC count plus poor peripheral perfusion (mean arterial pressure 50 mm Hg and/or absent peripheral pulses or capillary refilling time 3 s) in the absence of clinical dehydration.
dOne paper used Carrol ED, et al: The role of RANTES in meningococcal disease. J Infect Dis 2000; 182:363–366 and one referenced Abraham E, et al: Consensus conference definitions for sepsis, septic shock, acute lung injury, and acute respiratory distress syndrome: Time for a re-evaluation. Crit Care Med 2000; 28:232–235.
Summary of Variables With Significant Associations With Outcomes of Interest
| Variable | No. of Studies | No. of Participants With Outcome | No. of Participants Without Outcome | Pooled Estimate | Mean Value in Two Groups | ||
|---|---|---|---|---|---|---|---|
| Variables significantly associated with outcome of sepsis, severe sepsis, or septic shock | |||||||
| Decreased LOC | 4 | 172/369 | 354/2,565 | 9.8 (5.8–16.7) | 0.080 | 55.7 | |
| PRISM score | 2 | 1,695 | 3,612 | 6.0 (4.0–8.0) | 9.5 vs 3.5 | < 0.0001 | 93.3 |
| Variables significantly associated with outcome of mortality | |||||||
| Demographic variables | |||||||
| Severe acute malnutrition | 3 | 30/135 | 57/450 | 4.7 (1.4–16.3) | 0.094 | 57.8 | |
| Chronic conditions | 11 | 859/1,464 | 13,013/25,664 | 2.4 (1.4–4.1) | < 0.0001 | 85.7 | |
| Oncologic conditions | 8 | 104/402 | 616/2,422 | 2.3 (1.7–3.1) | 0.63 | 0.0 | |
| Clinical variables | |||||||
| Hypotension | 4 | 1,013/1,910 | 10,828/41,283 | 2.3 (1.8–2.9) | 0.052 | 61.1 | |
| Vasoactive agents | 20 | 623/739 | 1,831/3,475 | 6.5 (4.2–10.0) | < 0.0001 | 59.7 | |
| Vasoactive-inotropic score | 6 | 175 | 468 | 23.5 (3.4–43.6) | 49.3 vs 20.4 | < 0.0001 | 87.5 |
| Stroke index | 3 | 165 | 295 | 0.2 (0.1–0.4) | 1.8 vs 1.7 | 0.42 | 0.0 |
| Mechanical ventilation | 30 | 2,778/3,350 | 22,874/51,151 | 11.0 (7.4–16.3) | < 0.0001 | 84.2 | |
| Decreased LOC | 3 | 1,147/1,813 | 10,975/38,744 | 4.1 (2.9–5.9) | 0.22 | 33.6 | |
| Glasgow Coma Scale | 3 | 134 | 176 | –4.0 (–6.2 to –1.8) | 6.6 vs 11.0 | 0.10 | 56.5 |
| Laboratory variables | |||||||
| pH | 4 | 203 | 334 | –0.10 (–0.14 to –0.05) | 7.21 vs 7.31 | 0.077 | 56.1 |
| Lactate (mmol/L) | 17 | 900 | 3,867 | 1.9 (1.2–2.6) | 4.6 vs 2.7 | < 0.0001 | 94.4 |
| Base deficit | 6 | 570 | 2,377 | –3.2 (–5.8 to –0.6) | –9.1 vs –5.9 | < 0.0001 | 98.1 |
| Urea (mg/dL) | 4 | 326 | 1,750 | 1.5 (0.7–2.3) | 9.4 vs 6.2 | 0.075 | 56.6 |
| Creatinine (µmol/L) | 8 | 471 | 2,148 | 13.0 (4.6–21.5) | 62.4 vs 42.8 | < 0.0001 | 89.0 |
| Potassium (meq/L) | 3 | 268 | 1,447 | 0.2 (0.02–0.44) | 4.5 vs 4.3 | 0.92 | 0.0 |
| Platelet count (109/L) | 14 | 585 | 3,196 | –87 (–107 to –67) | 90 vs 178 | < 0.0001 | 90.9 |
| Fibrinogen (g/L) | 5 | 324 | 2,503 | –1.5 (–2.5 to –0.6) | 2.0 vs 3.6 | < 0.0001 | 97.9 |
| Albumin (g/L) | 3 | 237 | 563 | –4.3 (–8.4 to –0.2) | 31.0 vs 35.4 | < 0.0001 | 92.5 |
| Procalcitonin (ng/ml) | 9 | 463 | 1,266 | 4.0 (2.0–6.0) | 7.8 vs 4.8 | < 0.0001 | 92.2 |
| Alanine aminotransferase (units/L) | 3 | 298 | 1,262 | 10.1 (4.0–16.2) | 97.3 vs 65.8 | 0.46 | 0.0 |
| Organ dysfunction and illness severity variables | |||||||
| No. of organ dysfunctions | 4 | 1,065 | 4,683 | 0.9 (0.3–1.5) | 3.4 vs 2.5 | < 0.0001 | 92.6 |
| Renal dysfunction | 4 | 77/160 | 84/323 | 4.0 (1.0–18.4) | < 0.0001 | 86.2 | |
| Multiple organ dysfunction syndrome | 9 | 388/467 | 816/1,986 | 7.8 (3.9–15.6) | < 0.0001 | 75.2 | |
| PELOD | 12 | 442 | 1,748 | 6.1 (2.5–9.8) | 16.7 vs 8.7 | < 0.0001 | 97.7 |
| PELOD-2 | 3 | 110 | 1,320 | 8.7 (5.7–11.6) | 10.4 vs 1.2 | < 0.0001 | 91.2 |
| Sequential Organ Failure Assessment | 2 | 95 | 647 | 3.8 (2.7–4.9) | 9.9 vs 5.9 | 0.16 | 50.4 |
| Pediatric Sequential (Sepsis-related) Organ Failure Assessment | 4 | 595 | 756 | 4.8 (3.7–5.8) | 10.0 vs 4.2 | 0.52 | 0.0 |
| PRISM | 19 | 821 | 3,871 | 11.0 (5.6–16.5) | 22.5 vs 11.5 | < 0.0001 | 99.6 |
| PIM-2 | 2 | 63 | 397 | 12.1 (9.3–14.9) | 35.6 vs 18.0 | 0.33 | 0.0 |
| PIM-3 | 5 | 245 | 1,455 | 7.8 (2.5–13.1) | < 0.0001 | 89.1 | |
LOC = level of consciousness, PELOD = pediatric logistic organ dysfunction, PIM = Pediatric Index of Mortality, PRISM = Pediatric Risk of Mortality.
aNumbers reported are totals for those with and without the listed outcome for each parameter for continuous variables. For categorical variables, the numbers shown are the number with the parameter over the total with or without the outcome of interest.
bPooled estimate is for the odds ratio for categorical variables and the mean difference for continuous variables.
cThe mean values of nonsurvivors versus survivors are provided for all continuous variables.
dThe study by Thakkar et al (23) reported on two nonoverlapping cohorts of medical and surgical patients that were, therefore, analyzed separately and counted as two studies.